Centre to cap trade margins on non-scheduled cancer drugs to 30% of MRP
The Union government capped trade margins on non-scheduled anti-cancer drugs at 30% of the maximum retail price (MRP) to reduce patient costs. Current mark-ups average 170%, reaching 700% in some cases, with 75% of treatment costs borne out-of-pocket. This measure could lead to price reductions of up to 70% and annual savings of around ₹2,500 crore.